The seminonparametrie (SNP) 
INTRODUCTION
The statistical nonlinear mixed effects model has been used in population pharmacokinetic analysis since the pioneering work of Beal and Sheiner (1); see also refs. 2-4. These models account for interindividual variability in pharmacokinetic parameters and characterize the distribution of these parameters. The parameters vary from individual to individual due to variation in observable individual attributes and sampling variation in unobservable random effects that follow a distribution. The objectives of an analysis based on these models include estimation of population characteristics (mean, variance, etc.) of the pharmacokinetic parameters, assessment of the effect of individual attributes (weight, age, etc.) on the population characteristics, and computation of empirical Bayes estimates of an individual's pharmacokinetic parameters, which can be used in individual dosage adjustments (5) . The work of Mallet (6) , who proposed a nonparametric maximum likelihood (NPML) estimator, and his co-workers (7) , has generated interest in estimation of the entire distribution of the random effects and demonstrated the importance of nonparametric estimation of the distribution when there is cause to expect departures from standard specifications such as the normal or log-normal distribution. For example, departures such as multimodality or excess dispersion may be caused by omission of a relevant individual attribute from the description of pharmacokinetic parameters in the model.
Here we discuss a nonparametric method called SNP that is particularly relevant to population pharmacokinetic analysis using the nonlinear mixed effects model. It is based on a presumption that the distribution of the random effects has a smooth density. The method was originally developed for the models of interindividual heterogeneity that occur in labor economics (8) and has also been used in time series analysis (9) (10) (11) . It was adapted to nonlinear mixed effects models in (12) , which contains an application of the method to the population pharmacokinetics of phenobarbital and simulations assessing its ability to fit multimodal random effects densities. SNP is an acronym for seminonparametric, which is a usage that predates its application to nonlinear mixed effects models (13, 14) . With respect to nonlinear mixed effects models, smooth nonparametric would be a more meaningful interpretation of the acronym.
The SNP method simultaneously estimates the fixed effects and the entire distribution of the random effects of the nonlinear mixed effects model. Subsequent computations based on SNP estimates are convenient: statistical tests of the significance of individual attributes, tests for normality of the random effects density, empirical Bayes estimation of individual random effects, and simulation from the estimated density. The ability to simulate greatly facilitates computation of the population characteristics of pharmacokinetic parameters that are affected nonlinearly by the random effects.
Recently, Maitre et al. (15) and Mandema et aL (16) proposed examination of empirical Bayes estimates of the random effects from a preliminary model fit as a basis for determining which individual attributes influence the pharmacokinetic parameters. The SNP method is particularly well suited for this type of model-building strategy: Omitted individual attributes will tend to yield a fat-tailed or multimodal estimate of the random effects density. This will, in turn, produce disparate empirical Bayes estimates of individual effects, highlighting the omission.
In this article, we relate the SNP method to population pharmacokinetic analysis, exhibit a graphical model-building procedure that exploits the tendency for omitted individual attributes to produce disparate empirical Bayes estimates of individual effects, and illustrate by application to clinical data on quinidine concentration.
MAXIMUM LIKELIHOOD ESTIMATION
The SNP method is similar to the NPML method (6, 7) in that it invokes the likelihood principle as the basis for estimation. Mallet et al. (7) provides an excellent discussion of the underlying ideas, relating them specifically to population pharmacokinetics. Formulation of the likelihood involves two steps: specification of an individual likelihood function in terms of an individual's pharmacokinetic parameters and specification of the population likelihood in terms of a distribution for the pharmacokinetic parameters. In both methods this distribution is not restricted to belong to a parametric family but is estimated nonparametrically in its entirety; the methods differ in choice of nonparametric estimation method.
Individual Likelihood Function
Let Yu, 1 <j< Ji, be the observed concentration measurements on individual i, 1 < i<_N, at settings xu= (Xlo. .... , xro) of an r-vector of independent variables such as time, dose, rate of administration, etc. These are assumed to follow the intraindividual regression model
yu=f(xi:, fl,) q-eij
Th function f describes the pharmacokinetics in terms of the independent variables xu and the p~-vector of pharmacokinetic parameters fli = (fl ~e, fl2i,..., flpp3 specific to the individual; e 0 denotes the intraindividual error associated with the jth observation on individual i. The total number of observations is n = ~iN i J, -.
A common assumption is that the eu are independently and normally distributed with standard deviation proportional to level (17) , usually written as yij=f(xu, fli)(1 + e/j) where e o-are independently normally distributed with mean zero and variance o-z, so that eu=f(xu, fli)@. In contrast, the assumption of normally distributed errors with constant variance o -2 would have %= e0.
Specification of a distribution for this error completes the description of the individual likelihood. The error specification, taken together with the pharmacokinetic model f, implies a joint density for the observed concentration measurements on individual i. Write the density as where/~; is as above and cr is a p~ vector denoting parameters specific to the density such as parameters that characterize its second and higher moments. Under a proportional normal error model with independent errors, as in the example above, the assumption for eij implies that the joint density of the observed concentration measurements for individual i is Ji 
Population Likelihood Function
The pharmacokinetic parameters fll vary from individual to individual. Part of this interindividual variation may be explained by systematic dependence of pharmacokinetic parameters on demographic and other individual attributes, often called covariates. The unexplained portion is assumed to be random and is characterized by a probability density h. These dependencies are usually represented by an interindividual regression model for each element of j~i of the form
3ki=gk(wi, ~', Z~)
The interindividual regression function gk describes the interaction of systematic and random sources of variation associated with the kth pharmacokinetic parameter. In this function, w~=(wli ..... wli) is a /-dimensional vector of covariates, ~'=(7/1 ..... 7pr) is a pr-dimensional vector of unknown fixed effects, and zi = (zli, z2~ ..... zM~) is an M-dimensional vector of interindividual random effects with density h(z). Here, we use z where Sheiner and others (4, 18, 19) use 1/to denote a random effect.
Collect the functions gk together by writing g= (g~i, g2i ..... gp, i) to denote the system of equations that defines the interindividual regression model for all pharmacokinetic parameters. That is, ~i=g (wi, ?', zl) .
As discussed below, one objective of an analysis is determination of an appropriate model g. This involves choice of the individual attributes to make up wi and specification of a mathematical form to represent the nature of the dependence of fie on wi and z~.
An example is a log-additive specification of clearance CI~ for individual i as a function of body weight wit, an indicator variable w2i for ethanol abuse, and a random effect zl/ CI~= exp (70+ 71wie+ 72W2i" [-Zli) which would be one equation from the system of equations g (w, 7, z) . Note that the dimension of g is pa ,the dimension of z is M, and they need not be equal, as in the case where a pharmacokinetic parameter is assumed to be fixed (not random) across the population. Thus, if the pharmacokinetic parameter/3k~ were assumed fixed across the population, there would be no corresponding zk/in the regression model g~.
Collecting the parameters 7 and cr together into the single p~ vector r = (7, or), p~ =p~ +po the population likelihood can be written as
Here, the form ofpy differs from that given above because flr 7, zg) has been substituted to emphasize the dependence of the density on the covariates w and random effects z. Some individual attributes may change over the period of observation. This situation is accommodated by permitting the individual pharmacokinetic parameters to depend onj as well as i and by writing the interindividual regression model as flr 7, zi). For instance, in the example above write C/~=exp (7o+ 7,w:u+ 72wzi+zji) to indicate that measured body weight may change over the period of observation. In this case the joint density of the observations on individual i has the form 
SNP Estimation
In this framework, an important objective is determination of an appropriate interindividual regression model g (w, 7, z) from the data. Another is the determination of h, as h characterizes the population of individuals. Given g and h, estimation of and inference regarding the parameters r = (7, or) is of interest.
Nonparameteric estimation of h allows one to detect unusual features of the population such as multimodality or excess dispersion, which often indicates the presence of systematic interindividual variability and the need for a more refined interindividual regression model g. It also affords protection against incorrect assumptions regarding h that can bias estimates of 3 and lead to erroneous inferences.
Nonparametric estimation of h can be accomplished within the likelihood framework by maximizing the likelihood l (3, h), either simultaneously or sequentially, in the fixed parameters 3 and the density h. One maximizes with respect to h over a wide class of distributions. The NPML estimator is obtained when the class of distribution is completely unrestricted. A consequence is that NPML estimates are discrete densities that assign probability to a finite number of points.
Because the true density of the random effects associated with pharmacokinetic parameters is likely to be smooth, estimates ought have this characteristic as well. One can either obtain smooth estimates by smoothing the NPML estimator ex post or by imposing smoothness on the estimator ex ante. The SNP estimator is obtained by adopting the latter approach.
SNP estimates (f, h) maximize, simultaneously in r and h, the likelihood
The approach is based on the assumption that the true density h belongs to a class of smooth densities Jog described below. As a consequence, the estimate f~ is smooth. A mathematical description of the class jr is given by Gallant and Nychka (8) . Their most important requirement is that a density h in J~ must satisfy the smoothness restriction that h be at least M/2 times differentiable. A consequence of this restriction is that densities exhibiting unusual behavior such as kinks, jumps, or oscillation are excluded from consideration; however, densities in ocd may be skewed, multimodal, and fat-tailed or thin-tailed relative to the M-variate normal density. Thus, the assumption that the true density belongs to ~ allows for the possibility of a wide range of behavior, including the normal distribution, but rules out densities with unusual features that are unlikely to be characteristic of random effects associated with pharmacokinetic parameters. As a practical matter, it is the ability to represent a wide variety of interesting shapes such as multimodal densities and densities that are more spread out than the normal density (fat-tailed) that is important, as illustrated in the next section.
Gallant and Nychka have shown that a density from ~ can be represented as an infinite series expansion; a full description may be found in refs 8, 12 . The important consequence of this representation is that it suggests a convenient approximation h~r to h that can be substituted in sN(r, h) to facilitate computations. This approximation is a truncation of the infinite expansion to a finite number of leading terms. By appropriate choice of the number of terms retained, as determined by a tuning parameter K, the truncated expansion hK retains the ability of the infinite expansion to assume interesting shapes.
The truncated expansion is
where nM('llt, X) denotes the multivariate normal density of dimension M with mean/t and variance-covariance matrix I2 and R is an upper-triangular matrix. PK(u) is a polynomial of degree K in the components of u, that is, the polynomial that is the sum of all powers and cross-products of the components of u up to degree K. For technical reasons, the first coefficient of this polynomial is always put to one. As an illustration, if M = 2 and K= 2 then u = (ur, u2), and 2 2 P2(u) = aoo + alottl + aolu2 + a20ul + ao2u2 + al lulu2
The coefficients of this polynomial are (a00, al0, a01, a20, a02, all) with ao0-1. Note that the denominator is an easily computed weighted sum of products of the moments of the standard normal distribution (20, p. 47).
Let 0(1) be the vector whose elements are the coefficients of PK; let 0(2)=(rll, r12, r22, r13, r23, r33, 9 9 9 , rMM) be the vector whose elements are the distinct elements of R; let 0 = (0(1), 0(2)) ; and letp0 denote the dimension of the vector 0, which is determined solely by the degree K of PK and dimension M of z. The vector 0 completely describes the truncated expansion. We often write hx ('lO) to emphasize this fact. In the example, with M=2, K=2, 0(o=(aoo, al0, aoj, a2o, ao2, all), 0(2)=(r11, r12, r22), 0 = (0r 0~2)), SO that Po = 9, and the denominator of h2(" 10) is a weighted sum of products of moments to the 4th order of the standard normal distribution. Because the estimator f~K is actually a function of the parameters 0, and 0 is estimated, it may not be apparent that this estimator for h should be classified as nonparametric. The estimator is nonparametric because its form does not correspond to a particular distributional family, such as the normal or log-normal, and because it is capable of tracking features of the true underlying density in the same way as more familiar nonparametric estimators, such as that of Mallet (6) or kernel estimators (21) . The tuning parameter K is similar to the bandwidth used with kernel estimators. In particular, Gallant and Nychka (8) If the true density is assumed to have mean zero, that is, zh(z) dz=O, then this constraint may be imposed when computing /~K without altering the consistency result. When the constraint is imposed, the estimators with K= 0 and K= 1 are the same so that K= 2 is next in the progression. The off-diagonal elements of R may be constrained to be zero which attenuates estimated correlations if K> 0 but does not affect the consistency result. In summary, the estimate of h obtained by the SNP method will have all the usual desirable statistical properties of nonparametric estimators. Moreover, as discussed next, standard statistical methods for inference may be used.
Standard error and confidence intervals can be computed for the elements of r and characteristics of h using maximum likelihood formulas (22) .
The choice of the appropriate tuning parameter K may be addressed using standard statistical model selection criteria. Most criteria pick the value of K that minimizes an expression of the form s~(f, hx) + c(n)(pnct/ n), where p, ct =p, +po -1 if the constraint 5 zh(z) dz = 0 is not imposed and p,et =p,:
is a penalty factor designed to compensate for small sN(f, hK) achieved by fitting an overparameterized model. The standard criteria are the Schwarz or BIC with c(n) = (1/2) log n, the Hannan-Quinn (HQ) with c(n) = log log n, and the Akaike or AIC with c(n) = 1. These criteria have been extensively studied when (-n)sN(f,/~K) is replaced in the expression above by the optimized log likelihood of a linear regression model (22, 23, 24) . For the formula that relates this work to the present context see ref. 25, p. 366 . Note that the penalty decreases as one goes from BIC to HQ to AIC. Thus, K may, but need not, increase from BIC to HQ to AIC.
Our recommendation is to inspect plots of the estimated density for all choices of K between those chosen by the BIC and AIC inclusively and make a visual selection. Examples of such plots are in the next section. We cannot state the case for visual inspection better than Silverman (21): A natural method for choosing the smoothing parameter [K] is to plot out several curves and choose the estimate that is most in accordance with one's prior ideas about the density. For many applications this approach will be perfectly satisfactory. Indeed, the process of examining several plots of the data, all smoothed by different amounts, may well give more insight into the data than merely considering a single automatically produced curve. (p. 4) If one insists upon an automatic selection rule we recommend the HQ criterion because, upon checking several published applications of the SNP method in the econometrics literature, we found that the HQ criterion usually selected the same model that the authors of these articles had chosen after extensive diagnostic testing. The BIC nearly always selected a smaller model than the authors chose, and the AIC model nearly always selected a larger model.
One structural aspect of the truncation estimator hK deserves comment. If K= 0 then hK is the normal density; that is, the normal density is the leading term in the expansion. This is an advantage in applications when the normal distribution is a reasonable first approximation and one expects only modest departures from the normal such as an extra mode. Moreover, the fact that the leading term of the series is the normal density, provides a convenient means to test the hypothesis that the true density is normal. One can compare the optimized likelihood for K> 0 with that for K= 0 using, say, either the model selection criteria above or the asymptotic chi-square test. The asymptotic chi-square statistic for a choice between specifications K~<K.4 A having Pn~t=pH and PA, respectively, is 2n[sN(~,, hK,) --sN(rA, hrA)] on PA --P. degrees of freedom. In the econometrics literature it has been noted that the asymptotic chi-square tends to select unnecessarily large K, and its use has been largely abandoned in favor of the model selection criteria. Thus we prefer the model selection criteria for determining K.
For given K, the model selection criteria can also be used to determine if the current specification of g should be augmented by additional covariates. The model selection criteria are evaluated for both the current and augmented models. If the three model selection criteria select the larger model, one has rather persuasive statistical evidence in favor of the augmentation.
Imposing the constraint S z/~K(z) dz =0 usually has little effect on estimates and can be convenient when reporting results. Sometimes, however, the constraint increases the value of K required to obtain an adequate fit.
We recommend not imposing it unless it leaves the estimates of r, the selected value of K, and the visual appearance of the fitted density essentially unchanged. When K= 1, S zftK(z) dz = 0 imposes normality.
Putting the off-diagonal elements of R to zero improves numerical stability, especially when M is large. We recommend that it be imposed if estimates of r and the visual appearance of the fitted density are little changed. Under normality, this restriction imposes zero correlations.
A Fortran program implementing the SNP method is in the public domain. It is called nlmix and is available together with a User's Guide as a PostScript file either via ftp anonymous at ccvrl.cc.ncscu.edu (128.109.212.20) in directory pub/arg/nlmix or from the Carnegie-Mellon University e-mail server by sending the one-line e-mail message "send nlmix from general" to statlib@lib.stat.cmu.edu. (In the User's Guide, the meanings of n and N are permuted.) Nlmix computes parameter estimates, empirical Bayes estimates of the random effects, data for plotting, and simulations from the estimated density. Its use is illustrated in the next section.
PHARMACOKINETICS OF QUINIDINE

Kinetic Model
In their review article, Ochs et al. (26) summarize the literature, mostly experimental studies, on the pharmacokinetics of quidine:
Typical ranges for kinetic properties of quinidine in healthy persons weighing 80 kg are: apparent volume of distribution, V, 160 L to 280 L; elimination rate constant, ke, 0.06 hr -~ to 0.14 hr-m; and clearance, CI, 12 L/hr to 24 L/hr. Quinidine clearance is reduced in the elderly, in patients with cirrhosis, and in those with congestive heart failure. Oral quinidine is available either as relatively rapidly adsorbed conventional tablets (usually quinidine sulphate) or as a variety of slowly adsorbed sustained release preparations. The fraction available, F, is generally 0.7 or greater. Values of the first order absorption rate constant, k,, range from 0.63 hr -~ to 2.97 hr -1. Evidence of a dependence of F or ka on dosage form is conflicting. Quinidine is 70% to 90% bound to plasma protein, primarily to albumin but also to a number of other plasma constituents such as a~-acid glycoprotein. Binding is reduced in patients with cirrhosis, partly because of hyupoalbuminaemia, but is not influenced by renal insufficiency.
Recently, Fattinger et al. (27) obtained estimates within the ranges above from routine clinical data on 60 patients treated with quinidine for arrhythmias. They found that weight, age, and mild or moderate heart failure, and severe liver failure reduced clearance.
In the literature, a one-compartment open model with first-order absorption and a two-compartment open model with zero-order absorption are the two most common characterizations of quinidine disposition (26, 27, 28) .
Because the data used here have been analyzed using several statistical methodologies at an American Statistical Association Invited Paper Session (29) and by Verme et al. (18) using a one-compartment open model with firstorder absorption, that model is used here to permit comparison. Written in recursive form (19) , the model is For the non-steady state at a dosage time, t = tt
For the steady state at a dosage time, t = tt
Between dosage times, tt < t < tt+ i
where tt, I=0, 1 ..... are the times at which doses Dr are administered, C(t) is the concentration of quinidine at time t, Ca(tt) is the apparent concentration of quinidine in the absorption depot at time tt, Ca(to)= FDo/V, C(to)= 0, F is the fraction of dose available, ks is the absorption rate constant, k~ = CI/V is the elimination rate constant, Cl is the clearance, V is the apparent volume of distribution, and r~ is the steady state dosing interval.
Data
The data (18) Time periods over which patients were observed ranged form 0.13 to 8095.0. hr. The drug was administered as quinidine sulfate to 53 patients, as quinidine gluconate to 57 patients, and in both forms to 26 patients. Doses were adjusted for differences in salt content between the two forms by conversion of both forms to milligrams of quinidine base; doses ranged from 83 mg to 603 mg. Under steady state conditions, the mean dosing interval was 6.25 hr for the sulfate form and 7.70 hr for the gluconate form. Initial body weights ranged from 41 kg to 119 kg (s SD= 15.64); initial ages ranged from 42 years to 92 years (s SD=8.92); and heights ranged from 60 in to 79 in (s SD= .37). There were 91 Caucasians, 10 blacks, and 35 Latins; 91 nonsmokers and 45 smokers; 90 non-or social drinkers, 16 ethanol abusers, and 30 exabusers; and 40 with severe, 40 with moderate, and 56 with no or mild congestive heart failure. There were 84 patients with measured creatinine clearance greater than 50m l/rain throughout the observation period, 41 with creatinine clearance less than 50 ml/min, and 11 whose creatinine clearance varied about 50 ml/min. Albumin concentration (g/dl) measurements were available for some but not all patients so that this attribute cannot be incorporated into the interindividual regression model but its potential importance can be assessed graphically as seen below, ct,-acid glycoprotein concentration measurements (mg/dl) were taken periodically on all pateints and varied considerably within each patient; these ranged from 39 mg/dl to 316 mg/dl overall; the initial measurements on each patient had s 118.54 mg/dl (SD =46.23).
Analysis
The pharmacokinetic model, which corresponds tof(x, 13) of the previous section, has independent variables time, dose, and steady state dosing interval. The pharmacokinetic parameters that we considered were quinidien clearance CI, the apparent volume of distribution V, and the absorption rate constant ka. These three constitute the vector/3ig. Thej index indicates that some covariates that appear in the final specification of the interindividual regression function change over the period of observation.
These data do not permit estimation of the function of dose available F, therefore we specified F= I. As the lowest previous estimate of F reported (26) was 0.7, the largest possible upward bias in our estimates of V and CI is 40%. Stated differently, the pharmacokinetic parameters being estimated are CI/F and V/F.
The number of samples collected during the absorption phase were not sufficient to allow precise ew of the ka value. Common practice in this situation is to treat ka as fixed across the population, as opposed to random, and assign it a prespecified value based on previous results (18) . A value of 0.9 hr-' is reasonable with respect to the range of values 0.63 hr-' to 2.97 hr -~ above. The alternatives to this approach are to treat ka as either a fixed parameter to be estimated or as a random parameter. For completeness, we report results for all three cases: Case 1. ka fixed and prespecified at 0.9 hr -I. Case 2. /ca fixed and estimated. Case 3. ka random. In all cases, the constraint ~ zh(z)dz = 0 was imposed so the progression of SNP specifications is K= 0, 2, 3,...,
The intraindividual errors associated with measured plasma concentration were taken as independently normally distributed with constant coefficient of variation.
Maitre et al. (15) proposed a graphical model-building strategy in which empirical Bayes estimates based on a normal random effects density are plotted against potential covariates. We modify their procedure by exploiting the tendency, noted earlier, for omission of influential factors from the interindividual regression function g(w, ~, z) to induce dispersion or multimodality on nonparametric estimates of the interindividual random effects density h(z). Empirical Bayes estimates of the interindividual random effects computed from such estimates will be separated, a well-known phenomenon in the nonparametrics literature. The separation will be related to the omitted factors.
We recommend fitting models with no covariates and increasing K until empirical Bayes estimates of the random effects separate. This separation must occur for large enough K, which again is a well-known phenomenon in the nonparametrics literature. Next, plot these estimates against each potential covariate and look for a relationship. We expect the use of SNP, rather normal, empirical Bayes estimates to improve the performance of the Maitre et al. (15) procedure.
Because the graphics for Case 3 (ka random, M= 3) take more space to report than those for Cases 1 and 2 (k~ fixed, M= 2) and because we arrived at the same specification for the pharmacokinetic parameters in terms of the covariates in all three cases, we illustrate only the model-building strategy for Case 2. In all three cases, however, we report parameter estimates.
We begin the Case 2 analysis by fitting the SNP models K= 0,2,3 using a log-linear interindividual regression function (19) without covariates CI= exp (yl +z0 V = exp (~2 + z2) ka = exp (~,s). With these data it is essential to enforce positivity of the pharmacokinetic parameters during nonlinear optimization. In other data sets we found that this complication does not arise and enforcement of positivity during computations is not as important. One would, however, be unlikely to tolerate a specification whose converged estimates were negative for any admissible setting of the covariates or interindividual random effects, which is a tedious condition to verify. The log-linear specification enforces positivity during computations and eliminates the need to check for global positivity.
The nlmix program produces data both for plotting the estimated density and empirical Bayes estimates. We used Splus (30) to construct the graphical displays from nlmix graphics data. Figure 1 plots the estimated densities for K= 0 and K= 2 together with the corresponding empirical Bayes estimates 2; for each specification. A tendency for omitted, influential factors to induce multimodal estimates is seen in the K= 2 plots as is the separation of empirical Bayes estimates of the interindividual random effects.
The separation is due to omitted covariates in the interindividual regression. Thus, for each pharmacokinetic parameter, a visually apparent relationship in a scatterplot of each individual's estimated random effect on his or her demographic attribute suggests the importance of that attribute as a covariate in the interindividual regression function. The plot also suggests a functional form for g when the relationship is curvilinear. In assessing the form of the relationship, a regression line through the scatter plot helps guide the eye. When the data are categorical rather than measured along a continuum, boxplots take the place of scatterplots. Examples and a description of boxplots are in Fig. 2 . A plot of the estimated random effects against measured concentration reveals the importance of all omitted covariates taken as a group. This is a standard technique in linear regression analysis (using residuals, not estimated random effects) for models that have covariates and replicates or near replicates. Due to perfect correlation of residuals with observations, the technique cannot be used with a model that has only an intercept term. Here, regression residuals have been replaced by empirical Bayes estimates. As seen below, this seems useful in this application. However, our use of the technique in models without covariates as in Fig. 2 is analogous to regression that only has an intercept term. Thus, in general, one should interpret cautiously a plot of estimated random effects against measured concentration in a model without covariates.
The shallow slope of the regression of the empircal Bayes estimate of the V random effect on measured concentration in the lower panel of To determine these omitted covariates, we inspect the remaining plots in the upper panel of Fig. 2 . Slopes for the regressions for categorical variables are not comparable to the slopes for continuous variables; comparisons must be made within variable types. On this basis, creatinine clearance is the most important categorical variable. Next in importance is race. But the race relationship is due entirely to blacks, as seen from the graph, of which there are only 10 in the sample; thus, we do not inclUde race as a covariate. No other categorical variables seem as important, a t-acid glycoprotein concentration is the most important continuous variable. It is hard to judge between age, height, and weight as next in importance. Due to the weakness of the relationships seen in the upper panel of Fig. 2 , it is unlikely that all three covariates should enter the model. We selected weight. Table I , Fig. 3, and Fig. 4 .
In Table I , the inclusion of weight, creatnine clearance, and a l-acid glycoprotein concentration in the CI equation is strongly supported by all criteria in all specifications, K= 0,2,3. For the models with covariates, the conservative BIC selects the normal (K= 0), and HQ and AIC select the K= 2 specification. The shift from the K= 0 model without covariates to the K= 2 model once covariates are added seems to be due to a reduction in the estimated intraindividual coefficient of variation that allows a more precise estimate of the random effects density.
As seen from Fig. 3 , the covariates have removed the multimodality in the SNP (K= 2) estimate which suggests that there may no longer be omitted covariates. The lower panel of Fig. 4 indicates that there are no omitted covariates in the V equation; the slope of the regression of the V effect against measured concentration is fiat as are those for all variables.
In the upper panel, the slope of the regression of the CI effect against quinidine concentration has been considerably attenuated from Fig. 2 . It is interesting to note that the plots for weight, a l-acid glycoprotein concentration, and creatinine, and creatinine clearance are fiat. This attenuation and the shallow slopes of the regressions against the other variables suggest that there are no omitted covariates.
To confirm this impression, we computed the BIC, HQ, and AIC for inclusion of each of dosage form, age, height race, ethanol abuse, and congestive heart failure as an incremental variable in the equation for the K= 0 and K= 2 specifications. The BIC does not support inclusion of these covariates for either the K=0 or K= 2 specifications. The HQ supports inclusion of height for K= 2, otherwise it agrees with BIC. The AIC supports inclusion of congestive heart failure, ethanol abuse, race, and height for the K=0 specification; it agrees with HQ when K=2.
Because Fattinger et al. (27) reported lowered clearance for serious liver failure or serious congestive heart failure, we converted the trivariate ethanol abuse and congestive heart failure variables to bivariate categories by pooling non-or social drinkers with the exabusers and no or mild congestive heart failure patients with those experiencing moderate heart failure and repeated the above analysis, including both of the new variables simultaneously. For the K= 0 specification both the HQ and AIC support inclusion of these covariates. For K= 2, only the AIC supports inclusion.
The graphical analysis in Cases 1 and 3 leads to the same log-linear specification of the interindividual regression equation for CI and V as for Case 2. In Case 3, the ka equation is log-linear without covariates, k~ = exp (73 + Z3)"
Results
We found that no measured individual attributes affect the absorption rate ka or the apparent volume of distribution V. We found that clearance CI is positively related to weight, decreased in patients with impaired renal function (creatinine clearance >50), and decreased by increased levels of azacid glycoprotein concentration. We found weak statistical evidence that clearance may be reduced in patients with severe congestive heart failure or ethanol abuse. These results agree with previous results as summarized above. bpnet isthe effective number of parameters.
Csn(?, hx) is the negative of the optimized log-likelihood divided by the total number, n = 361, of measured concentrations. aBIC is the Schwarz model selection criterion. eHQ is the Hannan-Quinn model selection criterion. fAIC is the Akaike model selection criterion.
These data have also been analyzed (18) using the first-order method (18) and the program NONMEM (31) . The female patient was deleted from the analysis, ka was fixed at 0.894 hr -1, and the forms of the interindividual regression models used were different from those assumed here. Nonetheless, a qualitative comparison of results is possible, in particular with the Case 1 analysis reported here. Verme et al. (18) found, as we did, that clearance CI is decreased in patients with impaired renal function (creatinine clearance <50) and decreased by increased levels of al-acid glycoprotein concentration, with weak evidence for an effect of ethanol abuse. Our use of a graphical approach based on empirical Bayes estimates from a model without covariates seems to have saved some effort in that we arrived at a final specification without extensive intermediate fits.
Parameter estimates for Cases 1, 2, and 3 and specifications K= 0 and K= 2 are shown in Table II (z3) where z3 is interpreted as having zero variance in Cases 1 and 2. Estimates of the fixed effects ~ and the intraindividual coefficient of variation tr are remarkably stable across cases and specifications a are the estimated variances of the random effects, with the exception of var (z3). Correlation estimates are small and unstable; in Case 3 with K=0 it was necessary to constrain them to zero to achieve numerical stability in the optimizations. The estimate of the intrasubject coefficient of variation cr for the Case 1 analysis agrees well with that reported for both models (18) . Weight is in kg, al-acid glycoprotein concentration is in mg/dl, and creatinine clearance is in ml/min, Var(-) denotes the variance of a random effect and p(', -) a correlation. Cases differ with respect to which parameters are constrained. ~I'he estimate is constrained to have the value shown. ~The values listed are the actual estimates multiplied by 100. aNormal effects: maximum likelihood estimates with normal (K= 0) random effects density. eSNP effects: maximum likelihood estimates with SNP (K= 2) random effects density.
The population characteristics of [exp (z~), exp (z2), exp (z3)] are required to assess the population characteristics of the pharmacokinetic parameters as is seen from the interindividual regression equations for fl = (CI, V, k,) above. Since it is easy to simulate from the SNP density (12), as noted above, an estimate of a population characteristic such as a mean 8 exp (z0 = S exp (zOh(z)dz can be computed by Monte Carlo integration {zi}i=l from the estimated SNP density hK and by drawing a sample ~ I averaging d~ exp (z0 -(1/I) Y.~= 1 exp (~li). Similarly, a precentile would be computed as the corresponding percentile of {exp (~1;)}~=1. These computations can be made as accurate as desired by taking the number of Monte Carlo repetitions I large enough. Using this procedure, coefficients of variation, means, variances, and correlations of [exp (zj), exp (z2), exp (z3)] were computed and are shown in Table III for Cases 1, 2, and 3 and specifications K= 0 and 2. The estimate of the intersubject coefficient of variation for CI obtained here for the Case 1 analysis agrees well with that reported for the most comparable case of K=0 (18) .
The most notable feature of Table III is high coefficient of variation of exp (z3), which corresponds to absorption rate ks, and its interaction with the coefficient of variation of exp (z2), which corresponds to volume V. Treating ks as a fixed parameter to be estimated, Case 2, increases the coefficient of variation of volume over both the case when ka is fixed and specified, Case 1, and when treated as a random effect, Case 3. This is apparently due to an insuff• number of samples collected during the absorption phase. It is also interesting to note the stability of population characteristics of exp (z0, which corresponds to equinidine clearance CI, across Cases 1, 2, and 3.
Because the interindividual regression model is multiplicative, estimate of the population characteristics of the pharmacokinetic parameters are obtained by rescaling the random effect estimates. For instance, at a given setting of weight, a j-acid glycoprotein concentration, and creatinine clearance where ~ exp (zl) and var (exp zl) are the entries from Table III. For example, for a patient with median weight of 79.0 kg (based on the data), median a jacid glycoprotein concentration of 113.5 mg/dl, and creatinine clearance <50 ml/min, the estimate of mean clearance CI based on the Case 2 analysis with K=2 is 12.2 L/hr.
DISCUSSION
We propose the SNP method, taken from the econometrics literature, for the analysis of population pharmacokinetic data that can be described is in mg/dl, and creatinine clearance is in ml/min. CV(. ) denotes the coefficient of variation of a random effect, e(. ) denotes the mean, var (.) the variance, and p(.,' ) a correlation. Cases differ with respect to which parameter estimates are constrained, see Table II . The moments are computed by Monte Carlo integration using 2000 repetitions. bNormal effects: maximum likelihood estimates with normal (K= 0) random effects density. cSNP effects : maximum likelihood estimates with SNP (K= 2) random effects density.
by a nonlinear mixed effects model. The method produces smooth nonparametric estimates of the entire random effects density and simultaneous estimates of fixed effects by maximum likelihood. The benefits of estimating the entire distribution nonparametrically rather than a few leading moments have been discussed (7) . The SNP method is well suited to use of modelbuilding strategies that are able to exploit the inherent tendency of a nonparametric method to produce disparate empirical Bayes estimates when covariates have been omitted from the model, such as the graphical procedure proposed by Maitre et al. (15) and the automated procedures proposed by Mandema et al. (16) . We illustrate by using the graphical approach in an analysis of the population pharmacokinetics of quinidine. Because the SNP method is based on the principle of maximum likelihood and because the SNP density has a convenient representation, subsequent computations essential to a complete statistical analysis are straightforward: estimation of the precision of the estimates or fixed effects, statistical tests of the significance of covariates, tests for normality of the random effects density, empirical Bayes estimation of individual random effects, and estimation of population characteristics of pharmacokinetic parameters including those affected nonlinearly by the random effects. More elaborate, computationally intensive statistical analyses are also possible such as setting confidence bands on a marginal density of a random effect or pharmacokinetic parameter (10) or placing a global restriction on the density such as unimodality (9) .
The NPML (6, 7) method maximizes a likelihood over all distribution functions whereas the SNP method maximizes over a class of distributions restricted to have a smooth density. That is the difference between them. Both the NPML and SNP method require a complete specification of the intraindividual likelihood. The advantages of the SNP method, relative to the NPML method, are as follows: Unknown parameters that are fixed across individuals are estimated simultaneously with the distribution rather than by a two-step estimation procedure (7). Thus, for example, covariates in the interindividual regression for the pharmacokinetic parameters are easily accommodated. The SNP density estimate is inherently smooth; a subsequent smoothing computation is not required. Statistical inference is possible: one can test for normality and set confidence intervals on parameters.
If the true random effects distribution violates the smoothness assumption, however, the NPML estimator will be consistent and the SNP estimator will not. Empirical Bayes estimation of the random effects is convenient with both the SNP and NPML methods, and thus both allow use of a graphical model building strategy that exploits the tendency of nonparametric methods to produce disparate empirical Bayes estimates when the interindividual regression model is misspecified.
Mallet et al. (7) compare the features of nonparemetric methods to other procedures for the analysis of the nonlinear mixed effects model: the popular first-order (FO) approximation with extended least squares (ELS) estimation (1, 3, 32) , which provides estimates of fixed effects, allows empirical Bayes estimation based on normality, and is implemented in the powerful NONMEM package (31) , and in two-stage (TS) methods (2, 33) . Nonparametric methods are indicated when a knowledge of the entire distribution is required, not just first and second moments, or when an erroneous parametric assumption such as normality may be especially deleterious, as when computing empirical Bayes estimates. Nonparametric estimation of the entire distribution may be based on the use of TS methods; these methods, however, require a sufficient number of observations on each individual to allow accurate estimation of individual pharmacokinetic parameters. Thus, two-stage methods are usually not applicable to clinical data, which are typically sparse.
In addition, as we have illustrated here, nonparametric methods are inherently well suited to model building. Even when there is no other reason to use nonparametric methods, their ability to fragment empirical Bayes estimates, thereby exaggerating their relation to influential individual attributes, can be of value in allowing screening of a large number of factors for their potential as covariates.
